SHORT DESCRIPTION

A diagnostic technology that detects focal adhesion complex proteins in bodily fluids for rapid and non-invasive identification of podocytopathies.

BACKGROUND

Current diagnostic methods for podocytopathies rely on invasive kidney biopsies and slow testing processes. Healthcare providers need a rapid, non-invasive method to accurately evaluate podocyte injury and kidney health.

ABSTRACT

Northwestern researchers have identified several focal adhesion proteins present specifically in the plasma of patients experiencing podocyte effacement, a hallmark of various kidney diseases like minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). These newly identified biomarkers offer a non-invasive alternative to kidney biopsies for diagnosing podocytopathies. Preliminary studies show promising sensitivity and specificity, providing timely insights into kidney health and patient management. 

DEVELOPMENT STAGE 

TRL-3 - Experimental Proof-of-Concept Active R&D is initiated: Key detection functions have been validated in preliminary laboratory experiments.

APPLICATIONS

• Diagnosis of FSGS and MCD: Enables non-invasive assessment of podocyte health.
• Prognostic indicator for treatment or transplant: Monitors protein levels to predict outcomes.
• Secondary patient screening: Identifies podocytopathies in patients with abnormal proteinuria.
• Drug toxicity evaluation: Assesses podocyte response during therapeutic interventions.

ADVANTAGES

• First non-invasive test for podocyte injury: Eliminates the need for invasive kidney biopsies.
• Faster diagnosis: Provides rapid results compared to conventional methods.
• Enhanced sensitivity: Detects subtle changes in podocyte protein levels.
• Improved patient monitoring: Facilitates timely adjustments in therapy through continuous tracking.